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The unprecedented Ebola outbreak that devastated West Africa evolved within months from a regional outbreak to a global public
health emergency. While the rate of confirmed cases declined dramatically, sporadic clusters of Ebola virus disease (EVD) continue
well beyond the double incubation period of 42 days used to declare a nation Ebola-free. At the same time, evidence that the virus
persists in genital fluids and can be sexually transmitted, along with the potential for lingering virus in other body compartments to
permit recrudescence of EVD, has shaken our thinking of what it takes to achieve lasting control of an Ebola epidemic. A compre-
hensive response to the threat of persistence and sexual transmission of Ebola is required and should build on accessible longitudinal
medical care of survivors and accurate genital fluid testing for Ebola. Control of this and future Ebola outbreaks will depend on our
ability to recognize and respond to this persistence of the virus in those who survive.
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Few modern-era infectious diseases provoke the fear that Ebola
elicits. High mortality rates of the acute illness caused by this
filovirus are sufficient justification for this fear, but it is also
the relative ease by which Ebola is spread from person to person
that terrifies. Of the lessons learned during the recent outbreak
that devastated West Africa and triggered a global public health
emergency, the most ominous has been the recognition that
Ebola can persist in compartments of the body well after the
symptoms of acute infection abate and virus is cleared from
the circulation [1, 2]. Immune sanctuaries such as the cerebral
spinal and ocular fluids harbor virus and these reservoirs likely
serve as a source of recrudescent Ebola virus disease (EVD).
However, when Ebola persists in semen it becomes, as we
learned in 2015, a sexually transmitted infection [3, 4].
EVIDENCE OF THE PRESENCE OF EBOLA IN GENITAL
FLUIDS
Five studies conducted during previous outbreaks demonstrated
that Ebola could be detected, at least by polymerase chain reaction
(PCR), in the semen and vaginal fluid of EVD survivors following
clearance of viremia (Table 1) [5–9]. In these studies, Ebola virus
was detected in 12 of 15 (80%) men and in 1 of approximately 26
(4%) women. Prior to the current outbreak, the longest that virus
was detected by PCR in semen was 101 days after the onset of
symptoms (80 days after clearance of viremia) and 33 days from
symptom onset (21 days after clearance of viremia) for vaginal
fluid [7]. Repeat sampling to document clearance of virus from
genital fluid was not available, and thus the duration of shedding,
even in these few survivors, remains unknown. Data regarding the
shedding of infectious (ie, cultured) virus is even more limited.
Prior to the current epidemic, the longest reported duration
that virus was able to be cultured from semen was 82 days from
symptom onset, with a subsequent negative culture from a speci-
men obtained on day 704 [7].Based on these findings, survivors of
Ebola were advised to practice safe sex or abstinence for 3 months
after discharge from an Ebola treatment unit (ETU) [10].
A better understanding of the prevalence and potential sig-
nificance of Ebola virus persistence in urogenital shedding has
emerged from the current epidemic and suggests that survivors
shed infectious virus for considerably longer than previously
thought (Table 1). Researchers from the World Health Organi-
zation (WHO), US Centers for Disease Control and Prevention,
and Ministry of Health in Sierra Leone found that 49% (46/93)
of male survivors of EVD in that country who were within 10
months of release from an ETU had Ebola virus detected by
PCR in their semen, including 100% (9/9) of samples donated
2 to 3 months after onset of illness [11]. In this cohort virus was
detected in 65% (4/6) of survivors at 4 to 6months and in 26% (11/
43) 7 to 9 months after recovery from EVD, indicating that absti-
nence or safe sex for 3 months after discharge from an ETU is not
sufficient to prevent sexual transmission of Ebola virus [11].
SEXUAL TRANSMISSION OF EBOLA
Despite the detection of Ebola virus RNA by sensitive PCR
assays in genital fluids, the risk of sexual transmission was con-
sidered theoretical until the current epidemic, when theory be-
came reality. On March 20, 2015, a woman in Liberia was
diagnosed with EVD 30 days after the last confirmed patient
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in that country, and her only identified risk factor was unpro-
tected sexual contact with a male survivor of Ebola, who had
repeatedly undetectable Ebola in his blood by PCR 155 days
before their sexual encounter [3, 4]. PCR testing of the male
survivor’s semen after the woman became ill was positive
for Ebola virus. Virus was not able to be cultured from this
specimen, but the genetic similarity between the isolate in this
man’s semen and that from the blood of the infected woman
suggest this was a case of sexually transmitted Ebola [3, 4].
Although this is the most clearly documented case of sexual
transmission of Ebola virus, it is unlikely to represent a “one-
off” occurrence and, instead, indicates that sexual transmission oc-
curs but may be difficult to discern from other, more common,
modes of acquisition during an outbreak. Under conditions
when nonsexual contact with active cases of Ebola is driving trans-
mission, acquisition of Ebola virus by sexual intercourse would be
subsumed and likely unnoticed. As the outbreak wanes and there
are fewer opportunities for infection from nonsexual contact,
along with a peak in the number of survivors shedding virus, sex-
ual transmission would be revealed—a scenario that may have
played out in Liberia. Current recommendations from the
WHO and the Liberian Ministry of Health advise indefinite safe
sex until semen has been tested negative on 2 occasions or until at
least 6 months after the onset of symptoms of EVD [12].As testing
of semen for Ebola was not available in Liberia when the case de-
scribed above occurred, adherence to these recommendation
would have been unlikely to prevent this infection as the man con-
tinued to have evidence of Ebola in his semen 199 days after the
onset of EVD [4]. Importantly, there remain no recommendations
for women and no studies of vaginal shedding of Ebola virus.
PERSISTENCE OF EBOLA IN OTHER
COMPARTMENTS
Accumulating data indicate that the genital tract is not the only
site that permits the persistence of Ebola virus beyond the
clearance of virus from the circulation. A case of encephalitis
in an Ebola survivor whose cerebral spinal fluid (CSF) with
PCR-detected Ebola virus despite clearance of viremia has
been described—highlighting the capacity of this virus to pen-
etrate and persist in immune privileged compartments and its
ability to incite recrudescent disease [2]. More recently, virus
has been detected in at least 2 expatriate healthcare workers fol-
lowing convalescence from acute EVD including a case of virus
cultured from the vitreous of the eye greater than 3 months after
clearance of viremia and a case of recrudescence of viremia with
high levels of virus detected in the CSF more than 9 months fol-
lowing recovery from EVD [1, 13]. Both these healthcare work-
ers received at least 1 immunotherapeutic intervention when
first ill with EVD. It is plausible that these treatments, albeit po-
tentially life-saving, blunted host immune responses that then
permitted establishment of viral sanctuaries and the recrudes-
cence once their effects waned or viral replication was
stimulated.
THE CONSEQUENCES OF PERSISTENCE OF EBOLA
VIRUS IN SURVIVORS
The persistence of Ebola in different body compartments and
the potential for transmission either sexually via shedding or
by sexual and other contact with those experiencing recrudes-
cence threatens lasting control of the current epidemic. Histor-
ically, a country was declared Ebola-free following a period
of 42 days, the equivalent of two incubation periods, after the
last patient cleared virus from their blood or died. In prior out-
breaks, which were significantly smaller and where the high
mortality rates meant fewer survivors able to sexually transmit
the virus or suffer recrudescent disease remained, this worked
well. However, the 42 day rule has been demonstrated in the
current epidemic to be flawed.
Liberia has celebrated two “Ebola-free” declarations each of
which has been followed by reemergence of EVD. More recent-
ly, Sierra Leone suffered a new outbreak 69 days after being
declared free of Ebola and only 7 hours after the WHO declared
the end to all active chains of transmission in West Africa [14].
These sporadic outbreaks have been limited to a small number
of individuals with no reported contact with an active case of
Ebola. The potential routes by which these individuals were in-
fected are finite and include a zoonotic source, as is suspected to
have triggered this and other outbreaks. However, the clustering
of the cases in urban settings and the absence of a consistent
history of exposure to bats or other animals thought to carry
the virus makes this improbable. Instead, it is more likely,
given the evidence of viral persistence, that transmission from
a survivor shedding virus is what triggered these small
outbreaks.
This persistence of virus in body compartments and the
potential for sexual transmission from asymptomatic shedding
or recrudescent disease means one of the world’s most feared
Table 1. Persistence of Ebola Virus by Polymerase Chain Reaction and
Culture in Semen and Vaginal Fluid Among Ebola Virus Disease Survivors
[5–9]
Months After Symptom Onset
Prior to the Current Epidemic
Samples Tested PCR Positive (%)
<2 8 7 (88)
2–3 11 8 (73)
4–6 4 3 (75)
7–9 NA NA
The Current Epidemic
<2 ND ND
2–3 9 9 (100)
4–6 40 26 (65)
7–9 43 11 (26)
Abbreviations: NA, not available; ND, not done; PCR, polymerase chain reaction.
VIEWPOINTS • CID 2016:62 (15 May) • 1273
virus remains a threat until asymptomatic shedding of infec-
tious virus and the possibility of recrudescence ends. Therefore,
the point at which the 42 day countdown should begin is not
after the last person leaves an ETU but rather 42 days after
the last survivor who is shedding infectious virus ceases to do
so. At present, we do not know when that happens.
A COMPREHENSIVE APPROACH TO ADDRESSING
THE PERSISTENCE OF EBOLA IN SURVIVORS
IS ESSENTIAL
The recognition of a lingering risk of Ebola transmission from
some survivors requires a comprehensive mitigation response
that encompasses both individual and public health (Table 2).
Central to such efforts is a much better understanding of Ebola
persistence. The scope of the devastation caused by the recent
Ebola epidemic is unprecedented, but so too is the opportunity
to gain greater insights into Ebola convalescence—including the
longer term viral compartment dynamics and its role in post-
Ebola illnesses, recrudescence, and transmission. Lessons
learned from the intensive study of human immunodeficiency
virus (HIV) in compartments, including latently infected cells
and the genital tract, have been integral to developing approach-
es to viral eradication and interventions, as well as policies,
aimed at preventing transmission. This experience provides a
guiding framework for future Ebola research.
A lynchpin of this research needs to be the longitudinal study
of survivors to better ascertain the prevalence and duration of
genital shedding and to understand the phenomenon of recru-
descence. These data are necessary to develop informed policies
aimed at fully extinguishing outbreaks of Ebola and to empower
survivors with the ability to protect their loved ones. Ebola sur-
vivor research must be accompanied by Ebola survivor care.
Clinical services for survivors of this epidemic are scant and
the care that does exist is delivered in settings with few resourc-
es. Provision of medical care to Ebola survivors will improve
their quality of life and also allow for monitoring of persistent
sequelae from the acute infection and early detection of
recrudescence.
An immediate priority is increasing access to validated testing
of genital fluid for men and women who survived Ebola in West
Africa. At present, there is extremely limited genital fluid Ebola
PCR testing available in the region, despite public health guide-
lines recommending testing prior to engaging in unprotected
sex. Transitioning existing molecular Ebola diagnostic laborato-
ries, established during the height of the epidemic, from acute
diagnostic to longitudinal surveillance would expand testing of
genital fluids and could be leveraged to augment the diagnostic
testing available for patient care in the region. Although the
meaning of detection of Ebola by PCR in these fluids remains
less than certain, confirmed negative results are reassuring and
meet guideline recommendations. For those with detectable
virus in genital fluids, counseling can be provided to make
clear that detection of virus by PCR does not necessarily
mean infectious virus is present but that extra caution should
be taken given the possibility. Infectious virus has historically
been confirmed with the detection of replication competent
virus in cell culture [7]. On the other hand, it should be ac-
knowledged that the failure to grow virus in vitro in cell culture
should not be relied on as definitive evidence of noninfectious-
ness. For example, the recent case of sexual transmission in Li-
beria involved a male survivor whose semen had detectable
Ebola virus by PCR but was culture negative [11].
Complementing expanded testing must be an in-depth re-
search initiative to improve the sensitivity and specificity of in-
fectious virus detection in genital fluids. This can include
intracerebral inoculation in newborn mice and/or deep genome
sequence to determine if the entire viral genome is present or
just fragments. A comprehensive national and/or regional test-
ing program would also enable a definitive characterization of
the natural history of convalescent urogenital shedding, includ-
ing in both semen and vaginal fluid, of infectious Ebola virus so
that future public health recommendations can be based on a
solid foundation of scientific evidence.
Table 2. Proposed Elements of a Comprehensive Approach to Addressing
Risk of Sexual Transmission of Ebola
Element Rationale
Scale-up of clinical care centers for
survivors
• Treatment of post-Ebola ailments
• Counseling regarding transmission
risk
• Monitoring for recrudescent
disease
• Clinical research opportunities
Expanded validated genital fluid
testing for Ebola
• Inform risk potential and impact
behaviors
• Development of accurate Ebola
detection capacity
Establish longitudinal Ebola survivor
cohort studies
• Determination of prevalence,
duration and patterns of viral
shedding in genital fluids from men
AND women
• Examine techniques to improve
sensitivity of Ebola culture assays
• Determination of prevalence,
duration and clinical course of post-
Ebola aliments
• Assessment of psychosocial well-
being of survivors
• Interventional research
opportunities
Launch safety and efficacy testing
of novel compounds with anti-
Ebola activity
• Collection of safety, tolerability and
pharmacokinetics data.
• Pilot study of efficacy of agent(s) to
reduce viral shedding, penetrate
body compartments/sanctuary
sites, affect on post-Ebola aliments
Explore feasibility and efficacy of
vaccination of sexual partners of
Ebola survivors
• Tests strategic use of vaccination to
protect partners of Ebola survivors
Psychosocial research of Ebola
survivors
• Development of approaches to
support survivorship including
family and community reintegration,
sexual and reproductive health,
mental health, and stigma
mitigation.
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The persistence of Ebola virus in genital fluids offers an ad-
ditional opportunity to evaluate therapeutic interventions for
both efficacy and ability to penetrate immune sanctuary sites.
During the current epidemic, a number of novel treatment strat-
egies were trialed despite limited or no human safety or efficacy
data. In addition to collecting safety and tolerability data on
potential Ebola therapeutic agents now, the evaluation of such
novel compounds in survivors who continue to shed virus or
have certain Post-Ebola sequelae could provide important
information on the ability of these compounds to reduce or
eliminate virus replication and their ability to penetrate immune
privileged sites. Vaccination of sexual contacts of survivors is yet
another public health strategy that should be evaluated to limit
sexual transmission. In contrast to the challenge of conducting
clinical research while caring for acutely infected patients with
significant clinical needs during an outbreak of Ebola, these
studies would be conducted beforehand in a controlled environ-
ment that is safer for both provider and participant.
As the recent case of recrudescent EVD in a convalescing
healthcare worker demonstrates, there is also a potential that
persistence of virus can serve as smoldering embers from
which the fires of systemic dissemination can emerge. The
lack of clinical care for survivors in a healthcare landscape
that has been decimated by the Ebola outbreak means there
are too few opportunities to conduct surveillance for recrudes-
cent disease. The persistence of virus in the CSF, eye, and genital
tract also poses a risk to healthcare providers performing pro-
cedural interventions including ocular surgery, lumbar punc-
tures, or urogenital evaluations.
Importantly, beyond the personal and public health implica-
tions of persistence of Ebola virus in body compartments, the
uncertainty surrounding the shedding of virus in genital fluid
of survivors complicates survivor recovery. Stigma and social
ostracizing can disrupt quality of life and create barriers to
almost all aspects of normal community re-engagement [15].
There are few studies of the psychosocial vestiges of the recent
Ebola outbreak but what data are available make clear that
Ebola survivors have suffered considerable trauma, and it is
probably that fear that these survivors remain infectious that
feeds perceived and enacted stigma that impedes their ability
to regain pre-Ebola normalcy. Additional research is needed
to characterize the psychosocial aspects of survivorship and to
develop interventions that will assist survivors as they and their
families and communities adjust to a post-Ebola existence that
includes considerable uncertainty regarding the personal and
public health ramifications of this disease. Again, much can
be borrowed from the HIV prevention experience to test evi-
dence-based approaches to developing safer sex behaviors for
Ebola survivors.
Care must be taken with all these initiatives to ensure preser-
vation of dignity, respect, and support for survivors who have
suffered greatly. Ignoring these thousands of survivors risks
not only their own physical and mental health but also missing
the beginnings of the next outbreak.
BUILDING A ROBUST HEALTHCARE
INFRASTRUCTURE IN WEST AFRICA IS THE NEXT
PHASE OF THE GLOBAL EBOLA RESPONSE
Poverty and the absence of a robust healthcare infrastructure
contributed to a susceptible state in which an outbreak quickly
evolved into a global epidemic. Investment in the creation of a
new healthcare infrastructure is not only requisite for the care of
survivors and monitoring for ongoing viral shedding but is
critical to raise the standard of health among all people in West
Africa. We must not forget that many died from treatable illness
other than Ebola during this Ebola epidemic. Rebuilding what
was present before this epidemic only returns us to that initial
susceptible state. A new healthcare system would incorporate
epidemiologic training to track diseases and monitor health out-
comes, infection control education to limit the spread of diseases
especially among medical staff, expand diagnostic testing as many
hospitals lack the ability to measure even basic chemistries, and
increase access to primary care as a way to prevent illness. Addi-
tionally, improved access to clean water would have profound im-
plications on health and infection control. A robust healthcare
infrastructure would have played a tremendous role in limiting
the current Ebola epidemic, but more importantly, it will have
an even greater impact on almost every other more common
disease in West Africa.
CONCLUSIONS
The unprecedented Ebola outbreak that devastated West Africa
evolved within months from a regional outbreak to a global
public health emergency. It is clear that well-described nonsex-
ual modes of transmission drove the spread of the virus. How-
ever, the persistence of Ebola virus in immune privileged sites
represents a separate source for transmission that has been
underappreciated and that has complicated complete eradica-
tion of the virus from the human population in this region.
As the number of survivors from the current epidemic increas-
es, so too does the risk of sexual transmission and/or recrudes-
cent disease. Accompanying these threats is the opportunity to
dramatically improve our understanding of Ebola virus com-
partment dynamics to inform infection control measures, test
novel approaches to prevent viral shedding, and support the
mental health and well-being of survivors, all the while provid-
ing clinical care for those suffering from post-Ebola aliments. At
a time when reports are identifying who did not do what was
right in the global response to the latest Ebola outbreak, we
must not squander this invaluable opportunity to define the
outer limits of asymptomatic shedding in genital fluids and
the potential for recurrent disease, both of which threatens last-
ing control of an Ebola epidemic that, like the virus that caused
it, persists.
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